Clinical Trial | Treatment Groups | Mean Baseline BP (mm Hg) | Mean BP Reduction (mm Hg) | Persistence (% on Randomized Drug at End of Study) | Tolerability (% Withdrawn Because of Adverse Effects) |
---|---|---|---|---|---|
CAPPP9,15 | Captopril (n = 5,492) | 161.8/99.8 | 11/8* | Not reported | Not reported |
Diuretics/β-blockers (n = 5,493) | 159.6 /98.1 | ||||
STOP-210 | Felodipine/Isradipine (n =2,196) | 34.5 /17.5* | 66.2 | Not reported | |
Enalapril/Lisinopril (n = 2,205) | 194/98* | 34.5 /16.2* | 61.3 | Not reported | |
Diuretics/β-blockers (n = 2,213) | 34.8/16.6* | 62.3 | Not reported | ||
INSIGHT11 | Nifedipine (n =3,157) | 173/99* | 35/17* | 69.0 | 23.0 |
Hydrochlorothiazide/amiloride(n = 3,164) | 72.0 | 16.4 | |||
NORDIL12 | Diltiazem (n = 5,410) | 173.5/105.8 | 20.3 /18.7† | 77.0 | Not reported |
Diuretics/β-blockers (n = 5,471) | 173.4 /105.7 | 23.3/18.7† | 93.0 | Not reported |
BP = blood pressure.
* No difference between groups (P > .05).
† Difference between groups in systolic reduction (P < .001).